

Economic Plan

This document identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

Guideline

Atrial fibrillation: the management of atrial fibrillation.

List of Modelling Questions

Clinical questions by scope area	What is the most clinical and cost effective antithrombotic therapy for stroke prevention in people with AF? What is the most clinically and cost effective risk stratification tool for stroke or thromboembolic events in people with AF?
Population	People diagnosed with atrial fibrillation
Interventions considered for inclusion	Stroke prevention therapies evaluated: <ul style="list-style-type: none"> • Anti-platelets • Dual anti-platelets • Anticoagulants • No therapy Risk scoring tools employed to determine when a stroke prevention therapy should be considered: <ul style="list-style-type: none"> • HASBLED • CHA2DS2-VASc • CHADS2
Type of analysis	Cost utility analysis